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BACKGROUND
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combina-
tion with fulvestrant therapy, prolongs progression-free survival among patients 
with hormone-receptor–positive, human epidermal growth factor receptor 2 
(HER2)–negative advanced breast cancer. We report the results of a prespecified 
analysis of overall survival.
METHODS
We randomly assigned patients with hormone-receptor–positive, HER2-negative 
advanced breast cancer who had progression or relapse during previous endocrine 
therapy to receive palbociclib plus fulvestrant or placebo plus fulvestrant. We ana-
lyzed overall survival; the effect of palbociclib according to the prespecified 
stratification factors of presence or absence of sensitivity to endocrine therapy, 
presence or absence of visceral metastatic disease, and menopausal status; the ef-
ficacy of subsequent therapies after disease progression; and safety.
RESULTS
Among 521 patients who underwent randomization, the median overall survival 
was 34.9 months (95% confidence interval [CI], 28.8 to 40.0) in the palbociclib–
fulvestrant group and 28.0 months (95% CI, 23.6 to 34.6) in the placebo–fulves-
trant group (hazard ratio for death, 0.81; 95% CI, 0.64 to 1.03; P = 0.09; absolute 
difference, 6.9 months). CDK4/6 inhibitor treatment after the completion of the 
trial regimen occurred in 16% of the patients in the placebo–fulvestrant group. 
Among 410 patients with sensitivity to previous endocrine therapy, the median 
overall survival was 39.7 months (95% CI, 34.8 to 45.7) in the palbociclib–fulves-
trant group and 29.7 months (95% CI, 23.8 to 37.9) in the placebo–fulvestrant 
group (hazard ratio, 0.72; 95% CI, 0.55 to 0.94; absolute difference, 10.0 months). 
The median duration of subsequent therapy was similar in the two groups, and 
the median time to the receipt of chemotherapy was 17.6 months in the palbociclib–
fulvestrant group, as compared with 8.8 months in the placebo–fulvestrant group 
(hazard ratio, 0.58; 95% CI, 0.47 to 0.73; P<0.001). No new safety signals were 
observed with 44.8 months of follow-up.
CONCLUSIONS
Among patients with hormone-receptor–positive, HER2-negative advanced breast 
cancer who had sensitivity to previous endocrine therapy, treatment with palboci-
clib–fulvestrant resulted in longer overall survival than treatment with placebo–
fulvestrant. The differences in overall survival in the entire trial group were not 
significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135.)
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In 2018, approximately 266,000 new cases of breast cancer are estimated to occur in women in the United States, with 41,000 
deaths.1 Of these, hormone-receptor–positive 
breast cancer is the most common disease sub-
type.2 The cyclin-dependent kinases 4 and 6 
(CDK4/6) are key promoters of tumor growth in 
hormone-receptor–positive breast cancer, coop-
erating with estrogen-receptor pathway activa-
tion.3,4 Preclinical models of hormone-receptor–
positive breast cancer were highly sensitive to the 
CDK4/6 inhibitor palbociclib (Ibrance, Pfizer),4 
and in a subsequent phase 2 study (Palbociclib: 
Ongoing Trials in the Management of Breast 
Cancer [PALOMA]–1), palbociclib resulted in a 
progression-free survival benefit in patients with 
previously untreated, estrogen-receptor–positive, 
human epidermal growth factor receptor 2 
(HER2)–negative advanced breast cancer.5 Subse-
quently, the randomized, phase 3 trial PALOMA-2 
confirmed that palbociclib substantially pro-
longed progression-free survival, in combination 
with letrozole, as first-line therapy for estrogen-
receptor–positive, HER2-negative advanced breast 
cancer (hazard ratio for disease progression or 
death, 0.58; 95% confidence interval [CI], 0.46 
to 0.72).6
In the phase 3 trial PALOMA-3, we assessed 
whether treatment with palbociclib, in combina-
tion with fulvestrant, prolonged progression-free 
survival among patients with hormone-receptor–
positive, HER2-negative advanced breast cancer 
who had disease progression after previous en-
docrine therapy. The primary aim of the trial was 
met, with the trial showing significantly longer 
progression-free survival with combination palbo-
ciclib–fulvestrant therapy than with placebo–ful-
vestrant (median, 11.2 months [95% CI, 9.5 to 
12.9] vs. 4.6 months [95% CI, 3.5 to 5.6]; hazard 
ratio for disease progression or death, 0.50; 95% 
CI, 0.40 to 0.62; absolute difference, 6.6 months).7-9
Palbociclib and other CDK4/6 inhibitors in 
combination with endocrine therapy have become 
a standard of care on the basis of prolonged 
progression-free survival.5,10,11 However, long-term 
data regarding the effect of palbociclib on over-
all survival and the efficacy of subsequent ther-
apy have been limited. Here, we report the re-
sults of a prespecified analysis of the PALOMA-3 
trial in which we assessed the effect of palboci-
clib on overall survival and the efficacy of thera-
pies administered after disease progression.
Me thods
Trial Design and Patients
We conducted this prospective, international, 
randomized, double-blind, placebo-controlled, 
phase 3 trial to compare treatment with palbo-
ciclib–fulvestrant with placebo–fulvestrant in 
women with hormone-receptor–positive, HER2-
negative advanced breast cancer who had disease 
progression after previous endocrine therapy. 
Patients were randomly assigned, in a 2:1 ratio, 
to receive either palbociclib (at a dose of 125 mg, 
administered orally, once daily for 21 consecu-
tive days, followed by 7 days off, to comprise a 
complete cycle of 28 days) plus fulvestrant (at a 
dose of 500 mg, administered as an intramuscu-
lar injection according to standard of care, every 
14 days for the first three injections and then 
every 28 days) or placebo plus fulvestrant. Cross-
over between the two groups was not permitted.
Women were enrolled regardless of meno-
pausal status; postmenopausal women were at 
least 60 years of age, had undergone bilateral 
oophorectomy, or were younger than 60 years of 
age and had had a cessation of regular menses 
for at least 12 consecutive months. Premeno-
pausal or perimenopausal patients were required 
to receive concurrent goserelin for at least 4 weeks 
before the start of the trial intervention and to 
continue receiving it every 28 days for the dura-
tion of the trial intervention.
Randomization was stratified according to the 
presence or absence of documented sensitivity to 
previous endocrine therapy, the presence or ab-
sence of visceral metastatic disease, and meno-
pausal status at trial entry. Sensitivity to previous 
endocrine therapy was defined as either a docu-
mented clinical benefit (complete response, par-
tial response, or stable disease for ≥24 weeks) 
from at least one previous endocrine therapy 
regimen in the context of metastatic disease or 
the receipt of at least 24 months of adjuvant 
endocrine therapy before recurrence. Detailed 
methods of this trial have been reported previ-
ously.7,8 The protocol, with the statistical analy-
sis plan, is available with the full text of this 
article at NEJM.org.
End Points
The primary end point, investigator-assessed pro-
gression-free survival, was reported previously.7,8 
Overall survival, a prespecified key secondary 
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end point, was defined as the time from ran-
domization to death from any cause. Exploratory 
analyses included the investigator-assessed time 
receiving subsequent therapy (i.e., the time from 
randomization to the end of the immediate sub-
sequent line of therapy after disease progression) 
and time from randomization to the receipt of 
chemotherapy. Safety data were updated with 
additional follow-up time.
Oversight
The trial was designed by an academic steering 
committee that included representatives of the 
sponsor (Pfizer). Data were gathered by repre-
sentatives of the sponsor. All the authors con-
firm that the trial conformed to the protocol 
and attest to the accuracy and completeness of 
the data. All the authors and participating insti-
tutions have agreements with the sponsor regard-
ing confidentiality of the data. The first author 
wrote the first draft of the manuscript. All the 
authors had full access to the data and were in-
volved in interpreting the data, in writing and 
reviewing subsequent drafts of the manuscript, 
and in making the decision to submit the manu-
script for publication. A professional medical 
writer provided editorial assistance and was paid 
by the sponsor. AstraZeneca provided fulvestrant 
and had no involvement with the data collection 
or analysis or with any aspect of the manuscript 
preparation.
The trial was approved by the institutional 
review board at each site, and all the patients 
provided written informed consent before en-
rollment. The trial was conducted according to 
the principles of Good Clinical Practice and the 
Declaration of Helsinki. The conduct of the 
trial was monitored by an academic steering 
committee.
Statistical Analysis
The median overall survival among women with 
advanced or metastatic breast cancer who are 
treated with fulvestrant monotherapy was assumed 
to be 24 months. The trial was powered for its 
primary end point, progression-free survival. The 
planned final analysis of overall survival was per-
formed after approximately 60% data maturity 
(i.e., when death had occurred in 60% of the 
521 patients who had undergone randomiza-
tion), with one interim analysis of overall sur-
vival conducted at the time of the interim analysis 
of progression-free survival, when 28 deaths 
had occurred, and one interim analysis con-
ducted when 112 deaths had occurred. The 
family-wise error rate was protected at the one-
sided 0.025 level, with a hierarchical testing 
strategy between progression-free survival and 
overall survival.12,13 The median overall survival 
was estimated with the use of the Kaplan–Meier 
method, and the significance was determined 
with the use of a one-sided log-rank test with 
stratification according to presence or absence 
of sensitivity to previous endocrine therapy and 
the presence or absence of visceral metastases at 
randomization in the intention-to-treat popula-
tion. All the P values reported herein are two-
sided. The prespecified significance threshold 
was a two-sided P value of 0.047, which was ad-
justed for the planned interim analyses. The 
rank-preserving structural-failure time method 
was used as a sensitivity analysis to evaluate 
the effect of crossover to receive a CDK4/6 in-
hibitor in the placebo–fulvestrant group after the 
completion of the trial intervention. The rank-
preserving structural-failure time analysis is based 
on the intention-to-treat population and can 
provide a more accurate estimation of the treat-
ment effect by correcting for crossover between 
groups.14,15
R esult s
Patients
A total of 521 patients were enrolled between 
October 7, 2013, and August 26, 2014 (Fig. S1 in 
the Supplementary Appendix, available at NEJM 
.org). A total of 347 patients were randomly as-
signed to the palbociclib–fulvestrant group and 
174 to the placebo–fulvestrant group (intention-
to-treat population). A total of 345 patients in 
the palbociclib–fulvestrant group and 172 in the 
placebo–fulvestrant group received at least one 
dose of the assigned intervention (safety popu-
lation).
Double-blinding was maintained after both 
the primary analysis and the interim analysis. 
After a request from the investigator, unblinding 
occurred in 12 patients (3%) who received palbo-
ciclib and in 18 (10%) who received placebo. 
Most of these unblinding events (in 7 patients in 
the palbociclib–fulvestrant group and in 17 in the 
placebo–fulvestrant group) occurred after disease 
progression. 
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Overall Survival
The data regarding overall survival were analyzed 
at a cutoff date of April 13, 2018, with a median 
follow-up of 44.8 months and 60% data matu-
rity (310 deaths among 521 patients). A total of 
201 deaths occurred in the palbociclib–fulvestrant 
group, and 109 deaths in the placebo–fulvestrant 
group. The median overall survival was 34.9 
months (95% CI, 28.8 to 40.0) in the palbociclib–
fulvestrant group and 28.0 months (95% CI, 23.6 
to 34.6) in the placebo–fulvestrant group. The 
stratified hazard ratio for death was 0.81 (95% CI, 
0.64 to 1.03; P = 0.09) (Fig. 1A). The unstratified 
hazard ratio was 0.79 (95% CI, 0.63 to 1.00). The 
estimated rate of overall survival at 3 years in the 
Kaplan–Meier analysis was 50% (95% CI, 44 to 
55) in the palbociclib–fulvestrant group and 41% 
(95% CI, 33 to 48) in the placebo–fulvestrant group.
Subgroup analyses of overall survival were 
performed in prespecified subgroups (Fig. 1B). 
The three prespecified stratification factors were 
the presence or absence of sensitivity to previous 
endocrine therapy, the presence or absence of 
visceral metastatic disease, and menopausal sta-
tus. Among 410 patients with documented sensi-
tivity to previous endocrine therapy, the median 
overall survival was 39.7 months (95% CI, 34.8 
to 45.7) in the palbociclib–fulvestrant group and 
29.7 months (95% CI, 23.8 to 37.9) in the pla-
cebo–fulvestrant group (hazard ratio for death, 
0.72; 95% CI, 0.55 to 0.94) (Figs. 1B and 2A). 
Among 111 patients without documented sensi-
tivity to previous endocrine therapy (also referred 
to as intrinsic endocrine resistance), the median 
overall survival was 20.2 months (95% CI, 17.2 
to 26.4) in the palbociclib–fulvestrant group and 
26.2 months (95% CI, 17.5 to 31.8) in the pla-
cebo–fulvestrant group (hazard ratio, 1.14; 95% 
CI, 0.71 to 1.84; P = 0.12 for interaction) (Figs. 1B 
and 2B). In the updated analysis of PALOMA-3, 
which was conducted at a data cutoff of October 
23, 2015, patients with sensitivity to previous 
endocrine therapy had progression-free survival 
that was 7.8 months longer in the palbociclib–
fulvestrant group than in the placebo–fulvestrant 
group (hazard ratio for disease progression or 
death, 0.46; 95% CI, 0.36 to 0.59), whereas pa-
tients with intrinsic endocrine resistance had 
progression-free survival that was 2.3 months 
longer (hazard ratio, 0.69; 95% CI, 0.43 to 1.09) 
(Fig. S2 in the Supplementary Appendix). 
Among 311 patients with visceral metastatic 
disease, the median overall survival was 27.6 
months (95% CI, 24.4 to 31.2) in the palbociclib–
fulvestrant group and 24.7 months (95% CI, 20.8 
to 31.8) in the placebo–fulvestrant group (haz-
ard ratio for death, 0.85; 95% CI, 0.64 to 1.13) 
(Fig. 1B). Among 210 patients without visceral 
metastatic disease, the median overall survival 
was 46.9 months (95% CI, 39.3 to could not be 
estimated) in the palbociclib–fulvestrant group 
and 35.4 months (95% CI, 24.6 to could not be 
estimated) in the placebo–fulvestrant group 
(hazard ratio, 0.69; 95% CI, 0.46 to 1.04; P = 0.44 
for interaction) (Fig. 1B).
Among 413 postmenopausal patients, the 
median overall survival was 34.8 months (95% 
CI, 28.8 to 40.1) in the palbociclib–fulvestrant 
group and 27.1 months (95% CI, 22.8 to 32.1) in 
the placebo–fulvestrant group (hazard ratio for 
death, 0.73; 95% CI, 0.57 to 0.95) (Fig. 1B, and 
Fig. S3A in the Supplementary Appendix). Among 
108 premenopausal or perimenopausal patients, 
the median overall survival was 38.0 months 
(95% CI, 24.4 to could not be estimated) in the 
palbociclib–fulvestrant group and 38.0 months 
(95% CI, 22.2 to could not be estimated) in the 
placebo–fulvestrant group (hazard ratio, 1.07; 
95% CI, 0.61 to 1.86; P = 0.25 for interaction) 
(Fig. 1B, and Fig. S3B in the Supplementary Ap-
pendix).
An exploratory subgroup analysis evaluated 
overall survival according to ESR1 and PIK3CA 
mutation status, as assessed in baseline circulat-
ing tumor DNA. The median overall survival was 
longer with palbociclib–fulvestrant than with 
placebo–fulvestrant among patients with base-
line ESR1 mutations than among those without 
such mutations (absolute difference, 11.0 months 
among patients with ESR1 mutations and 4.7 
months among those without such mutations; 
P = 0.60 for interaction) (Fig. 1B). The absolute 
between-group differences in overall survival were 
similar among patients with baseline PIK3CA 
mutations and those without such mutations 
(6.4 months and 5.8 months, respectively; P = 0.64 
for interaction) (Fig. 1B).
Exposure to Trial Intervention
The median number of cycles of therapy received 
was 12 (interquartile range, 4 to 21) in the pal-
bociclib–fulvestrant group and 5 (interquartile 
range, 2 to 12) in the placebo–fulvestrant group. 
The Kaplan–Meier estimate of the rate of pa-
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tients continuing the trial intervention at 24 
months was 23% (95% CI, 19 to 28) in the pal-
bociclib–fulvestrant group and 10% (95% CI, 6 
to 15) in the placebo–fulvestrant group, and the 
rate at 36 months was 14% (95% CI, 11 to 18) 
and 5% (95% CI, 3 to 9), respectively (Fig. 3). At 
the time of the analysis, 35 patients (10%) were 
continuing to receive the trial intervention in the 
palbociclib–fulvestrant group (median duration, 
45.4 months; range, 44.2 to 51.4), as compared 
with 6 patients (3%) in the placebo–fulvestrant 
group (median duration, 44.7 months; range, 
44.2 to 45.6).
Disease Progression after Trial Intervention
In the intention-to-treat population, 389 patients 
(75%) received therapy after the end of trial in-
tervention. The median number of lines of treat-
ment received after disease progression was 2 
(range, 1 to 10) in the palbociclib–fulvestrant 
group and 3 (range, 1 to 10) in the placebo–ful-
vestrant group. The type of subsequent treat-
ment was similar in the two trial groups, except 
for subsequent CDK4/6 inhibitor treatment (Ta-
ble 1). Approximately 40% of the patients in each 
group received endocrine-based therapy as the 
immediate subsequent line of treatment.
Although the protocol did not allow patients to 
cross over to receive palbociclib, treatment with a 
CDK4/6 inhibitor in the subsequent or follow-
ing lines of treatment after the trial intervention 
occurred in 4% of patients in the palbociclib–
fulvestrant group and 16% of those in the pla-
cebo–fulvestrant group (Table 1). We performed 
a sensitivity analysis to explore the effect of this 
crossover on overall survival. The rank-preserv-
ing structural-failure time analysis suggested a 
small decrease in overall survival in the placebo–
fulvestrant group after correction for the cross-
over effect of 27 patients (median overall sur-
vival, 27.4 months [95% CI, 23.8 to 35.4]; stratified 
hazard ratio for death in the palbociclib–fulves-
trant group vs. the crossover-corrected placebo–
fulvestrant group, 0.78 [bootstrapped 95% CI, 
0.61 to 1.04]; unstratified hazard ratio, 0.77 
[bootstrapped 95% CI, 0.60 to 1.00]), as com-
pared with a median overall survival of 28.0 
months before adjustment.
Time Receiving Subsequent Line of Therapy
In exploratory analyses, we analyzed the time 
from randomization to the end of the immediate 
subsequent line of therapy after disease progres-
sion, which was 18.8 months (95% CI, 16.4 to 
20.5) in the palbociclib–fulvestrant group and 
14.1 months (95% CI, 12.0 to 16.7) in the pla-
cebo–fulvestrant group (hazard ratio, 0.68; 95% 
CI, 0.56 to 0.84; P<0.001). The time from ran-
domization to the first use of chemotherapy af-
ter disease progression was 17.6 months (95% CI, 
15.2 to 19.7) in the palbociclib–fulvestrant group, 
as compared with 8.8 months (95% CI, 7.3 to 
12.7) in the placebo–fulvestrant group (hazard 
ratio, 0.58; 95% CI, 0.47 to 0.73; P<0.001). The 
duration of the immediate subsequent line of 
therapy, according to type of treatment, was 
similar in the palbociclib–fulvestrant group and 
the placebo–fulvestrant group. Details are pro-
vided in Figures S4 and S5 in the Supplementary 
Appendix.
Adverse Events
The adverse-event profile of palbociclib–fulves-
trant remained consistent with that in the pri-
mary analysis (Table S1 in the Supplementary 
Appendix).7 Neutropenia of grade 3 or 4 oc-
curred in 70% of the patients receiving palboci-
Figure 1 (facing page). Overall Survival in the Overall 
Population and According to Subgroup.
Panel A shows overall survival in the intention-to-treat 
population (all the patients who underwent random-
ization). Tick marks indicate censored data. Panel B 
shows a subgroup analysis of overall survival. Boxes 
represent hazard ratios for death, with error bars indi-
cating 95% confidence intervals, in various subgroups 
according to characteristics of the patients at baseline. 
The prespecified stratification factors were the presence 
or absence of sensitivity to previous endocrine therapy, 
presence or absence of visceral metastatic disease, and 
menopausal status at trial entry. Race was reported by 
the patient; 2 patients (<1%) did not report their race 
on the case-report form. A total of 6% of the patients 
had estrogen receptor (ER)–negative, progesterone re-
ceptor (PR)–positive tumors. A total of 32% of the pa-
tients had received an initial diagnosis of metastatic 
disease or did not have data regarding a date of the 
 initial diagnosis of early-stage disease, so they were not 
included in the estimation of values for the disease-free 
interval. Data regarding ESR1 (encoding estrogen re-
ceptor 1) and PIK3CA (encoding phosphatidylinositol 
3-kinase catalytic alpha polypeptide) were from a sub-
group of patients who had samples of circulating tumor 
DNA that were tested for the mutations; 25% of the 
patients did not have adequate circulating tumor DNA 
for testing. NE indicates that the value could not be 
 estimated.
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clib–fulvestrant and in none of the patients re-
ceiving placebo–fulvestrant, anemia of grade 3 or 
4 occurred in 4% and 2% of the patients, respec-
tively, and thrombocytopenia of grade 3 or 4 oc-
curred in 3% and none of the patients, respec-
tively. Febrile neutropenia remained uncommon, 
occurring in 1% of the patients (3 of 345 pa-
tients) who received palbociclib–fulvestrant and 
in none of those who received placebo–fulves-
trant. Nonhematologic adverse events of grade 3 
or 4 were also uncommon. Events of grade 3 or 
4 that occurred at a frequency of more than 2% 
of the patients in the palbociclib–fulvestrant 
group were infections (in 5% of the patients in 
the palbociclib–fulvestrant group and in 3% of 
those in the placebo–fulvestrant group), fatigue 
(in 3% and 1%, respectively), and elevation in the 
aspartate aminotransferase level (in 3% and 2%).
Figure 2. Overall Survival According to Patients’ Sensitivity to Previous Endocrine Therapy.
Tick marks indicate censored data.
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Discussion
Although the results of the analysis of overall 
survival did not meet the prespecified threshold 
for statistical significance, the addition of palbo-
ciclib to fulvestrant resulted in an absolute pro-
longation of overall survival of 6.9 months among 
patients with hormone-receptor–positive, HER2-
negative advanced breast cancer who had disease 
progression after previous endocrine therapy. 
This result is consistent with the significant pro-
longation in progression-free survival that was 
observed with the addition of palbociclib to ful-
vestrant (Fig. S6 in the Supplementary Appendix). 
Among patients with previous sensitivity to endo-
crine therapy, one of the largest subpopulations 
enrolled in the trial, overall survival was pro-
longed by 10.0 months.
Multiple studies have shown that the addition 
of CDK4/6 inhibitors to endocrine therapy re-
sults in substantially prolonged progression-free 
survival. Improvement has been observed in com-
bination with aromatase inhibitors6,16-18 and ful-
vestrant7,19,20 for palbociclib, ribociclib, and abe-
maciclib therapy. A key issue has been the extent 
to which this benefit in progression-free survival 
translates to a prolongation of overall survival. 
In the PALOMA-3 trial, we found that the magni-
tude of improvement in progression-free survival 
(6.6 months longer with the addition of palboci-
clib to fulvestrant)9 translates directly to an im-
provement in overall survival of similar magnitude 
in the overall group of trial patients (6.9 months 
longer), but the difference did not reach statisti-
cal significance. This improvement was associ-
ated with a longer time from randomization to 
the end of the immediate subsequent line of 
therapy after disease progression and a longer 
time from randomization to the first use of che-
motherapy after disease progression among pa-
tients treated with palbociclib–fulvestrant than 
among those who received placebo–fulvestrant. 
Furthermore, with this longer follow-up, a sub-
group of patients who were treated with palboci-
clib–fulvestrant had a very long duration of dis-
ease control, with 14% of the patients continuing 
in the trial after 3 years of treatment with palbo-
ciclib–fulvestrant, as compared with 5% of those 
receiving placebo–fulvestrant.
Final data regarding overall survival from 
phase 3 trials of letrozole and CDK4/6 inhibitors 
are limited. These trials all have lower power for 
the statistical analysis of overall survival than for 
the statistical analysis of progression-free surviv-
al, and therefore the data presented in this article 
should be interpreted cautiously when deciding 
on the timing of CDK4/6 inhibitor therapy. Our 
data support the use of palbociclib–fulvestrant 
Figure 3. Time from Randomization to the End of the Trial Intervention.
Tick marks indicate censored data.
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in patients with disease recurrence during endo-
crine therapy after at least 2 years of adjuvant 
therapy or in patients who received endocrine 
therapy alone for metastatic disease with clinical 
benefit. For patients for whom first-line aroma-
tase inhibitor–based therapy is a standard of care 
or those who do not have a relapse while they are 
receiving an aromatase inhibitor, our findings do 
not inform the timing of palbociclib therapy.
The results regarding overall survival in the 
PALOMA-3 trial show the substantial challenges 
of finding a significant prolongation of overall 
survival in the context of a disease in which sur-
vival after disease progression is substantially 
longer than the time in the trial.21 To design a 
trial in this context that would detect a signifi-
cant improvement in overall survival to result in 
a hazard ratio for death of 0.80 would have re-
quired a much larger trial. Accordingly, an 80% 
power calculation would involve more than 700 
events, as compared with the approximate 46% 
power that results from the 310 deaths among 
the 521 patients who were enrolled in this trial. 
Future meta-analyses of CDK4/6 inhibitor studies 
Treatment Palbociclib–Fulvestrant Group (N = 347) Placebo–Fulvestrant Group (N = 174)
First Line Second Line
Third Line 
or Greater First Line Second Line
Third Line 
or Greater
number of patients (percent)
Any† 248 (71) 182 (52) 131 (38) 140 (80) 113 (65) 85 (49)
Chemotherapy
Any 138 (56) 133 (73) 121 (92) 87 (62) 76 (67) 76 (89)
Eribulin 7 (3) 13 (7) 42 (32) 3 (2) 11 (10) 29 (34)
Paclitaxel 31 (12) 39 (21) 42 (32) 31 (22) 18 (16) 28 (33)
Capecitabine 66 (27) 43 (24) 36 (27) 36 (26) 20 (18) 24 (28)
Doxorubicin 12 (5) 7 (4) 35 (27) 1 (1) 10 (9) 12 (14)
Vinorelbine 6 (2) 8 (4) 23 (18) 7 (5) 5 (4) 21 (25)
Gemcitabine 7 (3) 6 (3) 26 (20) 5 (4) 9 (8) 15 (18)
Cyclophosphamide 13 (5) 9 (5) 23 (18) 8 (6) 4 (4) 8 (9)
Carboplatin 5 (2) 6 (3) 19 (15) 1 (1) 5 (4) 7 (8)
Antihormonal agent
Any 100 (40) 40 (22) 38 (29) 52 (37) 29 (26) 31 (36)
Exemestane 57 (23) 20 (11) 21 (16) 25 (18) 15 (13) 13 (15)
mTOR kinase inhibitor
Any 40 (16) 17 (9) 20 (15) 21 (15) 12 (11) 13 (15)
Everolimus 40 (16) 17 (9) 20 (15) 21 (15) 12 (11) 13 (15)
CDK4/6 inhibitor‡
Any 6 (2) 2 (1) 6 (5) 9 (6) 6 (5) 15 (18)
Palbociclib 4 (2) 2 (1) 5 (4) 7 (5) 6 (5) 13 (15)
Ribociclib 1 (<1) 0 1 (1) 2 (1) 0 1 (1)
Abemaciclib 1 (<1) 0 0 0 0 2 (2)
*  Percentages in the first row were calculated on the basis of the number of patients in the intention-to-treat population. Percentages in the 
remaining rows were calculated on the basis of the number of patients who received any treatment after the discontinuation of the trial in-
tervention (i.e., the values in the first row). The term mTOR denotes mammalian target of rapamycin.
†  One patient with missing data or partial information about start and stop dates for all reported follow-up therapies was not included in this 
analysis.
‡  In the placebo–fulvestrant group, 27 patients received inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) after disease progression: 3 
patients received ribociclib only; 22 patients received palbociclib only, 2 of whom received palbociclib twice in combination with different en-
docrine therapies (24 counts in the table); and 2 patients received both palbociclib and subsequent abemaciclib (4 counts in the table).
Table 1. Systemic Anticancer Therapies Received as First, Second, and Third or Greater Lines of Subsequent Treatment by More Than 10% 
of the Patients in Either Trial Group Who Discontinued the Intervention.*
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may provide a more robust assessment of the 
effect of this class of drugs on overall survival, 
including in subgroups of patients. This trial also 
shows a further challenge of finding a significant 
benefit, because 16% of the patients in the pla-
cebo–fulvestrant group crossed over to receive a 
CDK4/6 inhibitor as subsequent therapy because 
of the commercial availability of this class of 
agents. Crossover to receive an investigational 
drug after disease progression may attenuate the 
observed advantage in overall survival22 and 
probably resulted in a modest prolongation of 
overall survival in the control group, thereby fur-
ther reducing the power of the trial to show a 
significant benefit.
A planned subgroup analysis of overall sur-
vival regarding the three prespecified stratifica-
tion factors identified the patients who derived 
the most benefit from palbociclib. In particular, 
patients with sensitivity to previous endocrine 
therapy had a substantial benefit, whereas those 
with intrinsic endocrine resistance had a limited 
benefit. This differential benefit in terms of over-
all survival closely mirrors the absolute prolon-
gation of progression-free survival that was ob-
served with palbociclib in these two populations. 
These data confirm that palbociclib was highly 
effective in augmenting responses in endocrine-
sensitive cancers, but the effect may be more 
limited in tumors with intrinsic endocrine resis-
tance. However, relatively few patients with in-
trinsic endocrine resistance were recruited in 
the trial, which limits the assessment of palbo-
ciclib in these patients.
Although palbociclib–fulvestrant resulted in a 
longer median overall survival than placebo–ful-
vestrant among postmenopausal patients but not 
among premenopausal or perimenopausal pa-
tients, this disparity can be attributed in part to 
the small size of the subgroup of premenopausal 
or perimenopausal patients and may also reflect 
variance in the proportion of patients with in-
trinsic endocrine resistance in the two subgroups. 
In the subgroup of premenopausal or perimeno-
pausal patients, the percentage of patients with 
intrinsic endocrine resistance was higher than in 
the postmenopausal subgroup (30% vs. 19%).23 
Because patients with intrinsic endocrine resis-
tance may have limited benefit from endocrine 
therapy in combination with palbociclib, the 
overall survival benefit is difficult to ascertain. 
Furthermore, an imbalance in certain prognostic 
factors between the palbociclib–fulvestrant group 
and the placebo–fulvestrant group in the sub-
group of premenopausal or perimenopausal pa-
tients favored the control group. Premenopausal 
or perimenopausal patients who had been ran-
domly assigned to the placebo–fulvestrant group 
had received fewer lines of previous therapy than 
those who had been randomly assigned to the 
palbociclib–fulvestrant group (lines of previous 
therapy, 0 or 1: 72% of the patients in the pla-
cebo–fulvestrant group vs. 58% of those in the 
palbociclib–fulvestrant group), and fewer patients 
were 40 years of age or younger (22% of patients 
in the placebo–fulvestrant group vs. 35% of 
those in the palbociclib–fulvestrant group).23
The duration of the immediate subsequent line 
of therapy after disease progression after the 
completion of trial intervention was similar in 
the palbociclib–fulvestrant group and the placebo–
fulvestrant group, which shows that standard 
treatments had similar efficacy after progres-
sion while patients were receiving palbociclib or 
placebo (Fig. S5 in the Supplementary Appendix). 
Research on the mechanisms of resistance to 
CDK4/6 inhibitors in the PALOMA-3 trial indicat-
ed that disease progression during palbociclib–
fulvestrant treatment was due predominantly to 
endocrine resistance.24,25 Analysis of circulating 
tumor DNA in plasma samples obtained at the 
end of the trial intervention revealed that the 
genetic profile at the end of the trial intervention 
was largely similar in patients treated with palbo-
ciclib and those who received placebo, with the 
exception of retinoblastoma (RB1) mutations that 
were selected in 5% of the patients who had 
progression during palbociclib treatment.24 The 
data regarding overall survival in this trial sug-
gest that the low rate of RB1 mutations selected 
by palbociclib has no overall detectable effect on 
either overall survival or sensitivity to subsequent 
therapies after progression during trial treatment.
Taken together, the data from the PALOMA-3 
trial showed that palbociclib in combination with 
fulvestrant led to a 6.9-month prolongation of 
overall survival, although the finding did not 
reach significance in the intention-to-treat popu-
lation. In the subgroup of patients with sensitiv-
ity to previous endocrine therapy, overall survival 
was 10 months longer with palbociclib–fulves-
trant than with placebo–fulvestrant.
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